MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

PURPOSE: Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J., Grisham, Rachel N., Banerjee, Susana, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L., Hilpert, Felix, Oza, Amit M., Westermann, Anneke, Oehler, Martin K., Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Drill, Esther, Cibula, David, Moore, Kathleen N., Christy-Bittel, Janna, del Campo, Josep M., Berger, Regina, Marth, Christian, Sehouli, Jalid, O’Malley, David M., Churruca, Cristina, Boyd, Adam P., Kristensen, Gunnar, Clamp, Andrew, Ray-Coquard, Isabelle, Vergote, Ignace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655017/
https://www.ncbi.nlm.nih.gov/pubmed/32822286
http://dx.doi.org/10.1200/JCO.20.01164

Ejemplares similares

Ejemplares similares